澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

RHYTHM BIOSCIENCES LTD

0.080

0.000

成交量：5.18萬

成交額：4,148

市值：2,830.93萬

市盈率：-4.52

高：0.081

開：0.080

低：0.080

收：0.080

52周最高：0.280

52周最低：0.075

股本：3.54億

流通股本：1.88億

量比：0.34

換手率：0.03%

股息：- -

股息率：- -

每股收益(TTM):-0.018

每股收益(LYR):-0.018

淨資產收益率：-276.00%

總資產收益率：-96.19%

市淨率：7.78

市盈率(LYR):-4.52

資料載入中...

總覽公司新聞資訊公告

Rhythm Biosciences宣佈任命兩位非執行董事，8月27日正式生效

Rhythm Biosciences與英國Digistain公司簽署東南亞市場Genetype產品分銷協議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/RHY.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","market":"AU","secType":"STK","nameCN":"RHYTHM BIOSCIENCES LTD","latestPrice":0.08,"timestamp":1789539120000,"preClose":0.08,"halted":0,"volume":51808,"delay":0,"changeRate":0,"nameEN":"RHYTHM BIOSCIENCES LTD","floatShares":188306561,"shares":353866857,"eps":-0.0177,"marketStatus":"未開盤","change":0,"latestTime":"09-16 16:12:00 AEST","open":0.08,"high":0.081,"low":0.08,"amount":4148,"amplitude":0.0125,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0177,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.08,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.3372363385664047,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RHY.AU","preClose":0.08,"auctionPrice":0.08,"auctionVolume":43000,"auction":3,"marketStatus":"盘后竞价","timestamp":1789538404662}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","floatShares":188306561,"roa":"-96.19%","roe":"-276.00%","lyrEps":-0.0177,"volumeRatio":0.3372363385664047,"shares":353866857,"dividePrice":0,"high":0.081,"amplitude":0.0125,"preClose":0.08,"low":0.08,"week52Low":0.075,"pbRate":"7.78","psRate":"16.26","week52High":0.28,"institutionHeld":0,"latestPrice":0.08,"eps":-0.0177,"divideRate":0,"volume":51808,"delay":0,"ttmEps":-0.0177,"open":0.08,"prevYearClose":0.135,"prevWeekClose":0.083,"prevMonthClose":0.087,"prevQuarterClose":0.091,"fiveDayClose":0.082,"twentyDayClose":0.082,"sixtyDayClose":0.093,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHY.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-07-27","symbol":"RHY.AU","type":"split","dateTimestamp":1595772000000,"forFactor":875,"toFactor":1000,"ratio":0.875}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHY.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHY.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1178839475","title":"Rhythm Biosciences宣佈任命兩位非執行董事，8月27日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1178839475","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178839475?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 06:08","pubTimestamp":1787695689,"startTime":"0","endTime":"0","summary":"生物科技公司Rhythm Biosciences（RHY.AU）今日发布公告，宣布任命Maureen Baker和Carl Stubbings为非执行董事。据悉，该项人事任命将于2026年8月27日正式生效。\n这一董事会层面的新变动，标志着公司在治理结构上的进一步调整与优化。两位新任董事的加入，料将为公司带来更为多元化的经验与视角。\n作为一家专注于生物科技领域的企业，Rhythm Biosciences此次人事布局，或为其未来发展战略注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128067080","title":"Rhythm Biosciences與英國Digistain公司簽署東南亞市場Genetype產品分銷協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1128067080","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128067080?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 05:59","pubTimestamp":1772575193,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences有限公司宣布与英国Digistain有限公司正式达成战略合作，双方签署了针对东南亚市场的Genetype产品分销协议。该协议标志着公司在亚太地区业务拓展取得重要突破，将为东南亚地区提供先进的基因分型检测解决方案。\n此次合作将充分发挥Digistain在英国市场的渠道优势，结合Rhythm Biosciences在生物诊断领域的技术专长，共同推动Genetype产品在东南亚医疗市场的商业化进程。协议内容涵盖多个国家与地区的独家经销权，预计将显著提升公司产品在国际市场的渗透率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}